文献速递肝病胰腺与胆道疾病

GLP-1/FGF21双激动剂HEC88473治疗MASLD合并T2DM的安全性和疗效:一项随机、双盲、安慰剂对照研究

Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
PubMed 文献 · J Hepatol · 2024-12-19

这项随机、双盲、安慰剂对照的Ib/IIa期多剂量递增试验纳入60例MASLD合并T2DM患者,按10:2随机接受HEC88473(5.1、15.3、30.6、45.9或68.0 mg)或安慰剂每周皮下注射5周。结果显示HEC88473 generally安全且耐受良好,30.6 mg队列MRI-PDFF相对均值变化最大达-47.21%(p=0.0143),安慰剂组为-15.05%;68.0 mg队列HbA1c均值变化最大为-1.10%,安慰剂组为-0.31%。

要点

  • HEC88473每周皮下注射5周总体安全、耐受良好,最常见不良事件为胃肠道疾病(n=29,48.3%)。
  • 30.6 mg队列MRI-PDFF相对均值变化最大达-47.21%(p=0.0143),安慰剂组为-15.05%。
  • 68.0 mg队列HbA1c均值变化最大为-1.10%,安慰剂组为-0.31%。

核心结论

  • 5周HEC88473治疗总体安全且耐受良好,观察到肝脏脂肪减少、血糖控制改善、胰岛素抵抗和脂质代谢改善等多重积极效应,共同提示代谢综合征的全面改善。
  • 作者认为HEC88473可能是该患者人群中有前景的治疗选择。

研究设计与样本

  • 随机、双盲、安慰剂对照、多剂量递增的Ib/IIa期试验。
  • 60例MASLD合并T2DM患者按10:2随机接受HEC88473(5.1、15.3、30.6、45.9或68.0 mg)或安慰剂,每周皮下注射,持续5周。

主要发现

  • 治疗5周后MRI-PDFF呈剂量比例性降低,30.6 mg队列相对均值变化最大达-47.21%(p=0.0143),安慰剂组为-15.05%。
  • 基线PDFF>8%的患者中,>30%相对降低的患者比例更高。
  • 5周HEC88473治疗显著降低HbA1c以及空腹和餐后血糖水平,68.0 mg队列HbA1c均值变化最大为-1.10%,安慰剂组为-0.31%。
  • 参与者的脂质谱也观察到改善。
  • 大多数不良事件为轻至中度,最常见不良事件为胃肠道疾病(n=29,48.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) are key regulators of glucose and lipid metabolism. In the present study, we assessed the safety and efficacy of a novel GLP-1/FGF21 dual agonist HEC88473 for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) combined with type 2 diabetes mellitus (T2DM). METHODS: This was a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib/IIa trial. Sixty patients with MASLD and T2DM were randomized (10:2) to receive HEC88473 (5.1, 15.3, 30.6, 45.9, or 68.0 mg) or placebo via weekly subcutaneous injection for 5 weeks. RESULTS: After 5 weeks of treatment with HEC88473, MRI-proton density fat fraction (MRI-PDFF) was reduced in a dose-proportional manner. The largest relative mean change reached -47.21% (p = 0.0143) in the 30.6 mg cohort, compared with -15.05% in the placebo group, with a higher proportion of >30% relative reductions in patients with baseline PDFF >8%. The 5-week treatment with HEC88473 significantly reduced levels of HbA1c (glycated hemoglobin), as well as fasting and postprandial glucose levels. The largest mean change in HbA1c was -1.10% in the 68.0 mg cohort, compared with -0.31% in the placebo group. Improvement was also observed in participants' lipid profiles. Most adverse events were mild to moderate in severity. The most frequently reported adverse events were gastrointestinal disorders (n = 29, 48.3%). CONCLUSIONS: Herein, we report the clinical safety and proof-of-concept data for the GLP-1/FGF21 dual agonist HEC88473. A 5-week treatment with HEC88473 was generally safe and well tolerated, with multiple positive effects observed, including reduced liver fat, and improved glycemic control, insulin resistance and lipid metabolism, together indicating comprehensive improvement in metabolic syndrome. IMPACT AND IMPLICATIONS: In this randomized, double-blind, placebo-controlled phase Ib/IIa study, we assessed clinical safety, pharmacodynamic and pharmacokinetic data of the GLP-1/FGF21 dual agonist HEC88473 in patients with MASLD (metabolic dysfunction-associated steatotic liver disease) and T2DM (type 2 diabetes mellitus). HEC88473 was generally safe and well tolerated. The GLP-1/FGF21 dual agonist significantly reduced the hepatic fat fraction assessed using MRI-proton density fat fraction, and improved glycemic control and lipid profiles with only 5 weeks' treatment, leading to comprehensive improvement in metabolic syndrome. The present results suggest that HEC88473 could be a promising treatment option in this patient population. CLINICAL TRIAL NUMBER: Chinese Drug Trial Identifier (http://www.chinadrugtrials.org.cn/index.html): CTR20211088. CLINICALTRIALS: GOV: NCT05943886.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Xiang L, Wang G, Zhuang Y, et al. Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study. J Hepatol. 2024. PMID: 39709140. doi:10.1016/j.jhep.2024.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。